Skip to content Skip to footer

News

SimAbs Secures €1 Million Investment for Advanced Antibody Production

SimAbs' Continuous Manufacturing Platform Revolutionizes Biotherapeutics and Diagnostics Production     Diepenbeek, BioVille, Belgium, September 25, 2023 – SimAbs announces a successful capital raise of 1 million euro, marking a significant milestone in the company's journey since its inception in 2019. This funding, primarily sourced from a consortium of renowned entrepreneurs and business angels…

Read More